Jill Wu, an analyst from CMB International Securities, maintained the Buy rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990 – Research Report). The associated price target was raised to HK$299.93.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jill Wu has given her Buy rating due to a combination of factors including Sichuan Kelun-Biotech’s impressive financial performance and strategic advancements in their drug pipeline. The company demonstrated strong revenue growth in 2024, primarily driven by milestone payments from global partnerships and the launch of new drugs, which reflects its robust collaboration efforts and innovative product development.
Moreover, the company’s focus on commercializing next-generation ADC therapeutics, particularly the Sac-TMT drug, which has shown significant clinical benefits, supports the positive outlook. The expansion of their commercial team and the strategic utilization of Kelun Pharma’s industry resources further bolster confidence in achieving substantial sales targets. Additionally, Kelun-Biotech’s ongoing innovation in ADC strategies across oncology and non-oncology fields highlights its potential for continued growth and market leadership.